Kaydence Pharma Announces Successful Completion of Pre-IND Meeting with FDA

Kaydence Pharma AS the development stage pharmaceutical company spun-out of NattoPharma in 2017 reported that it has successfully completed a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA). At the meeting, the FDA addressed questions regarding key components of the planned IND application and the clinical/regulatory pathway for MQ7, Kaydence Pharma's novel drug candidate for the treatment of arterial stiffness in stable renal transplant recipients with subclinical vitamin K deficiency.